Antibodies directed against nerve growth factor (NGF)
US9951126B2 · kind B2 · utility
0Cited by
4References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 31, 2014 |
| Grant date | Apr 24, 2018 |
| Priority date | — |
| Expiry date | Dec 31, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to an isolated immunoglobulin heavy chain polypeptide and an isolated immunoglobulin light chain polypeptide that binds to Nerve Growth Factor (NGF). The invention provides an NGF-binding agent that comprises the aforementioned immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide. The invention also provides vectors, compositions, and methods of using the NGF-binding agent to treat an NGF-mediated disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.